Literature DB >> 15315835

Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine.

Bruno Guy1, Pornthep Chanthavanich, Sophie Gimenez, Chukiat Sirivichayakul, Arunee Sabchareon, Sarah Begue, Sutee Yoksan, Christine Luxemburger, Jean Lang.   

Abstract

Sera from Thai children immunized with a live-attenuated tetravalent dengue virus vaccine or from naturally infected age-matched site-control subjects were examined for immune enhancement capacity by a highly reproducible flow cytometric assay in Fc receptor-bearing K562 human cells. None of the sera under study corresponded to cases of severe dengue disease. In parallel assays employing each dengue virus serotype, we found no or only minimal antibody-dependent enhancement (ADE) when sera from vaccinated or control subjects were used at a low serum dilution [1/12] that approximated the in vivo condition. Among sera that exhibited homotypic neutralizing antibody activity against DV1-3, the level correlated with absence of ADE or infection with the respective serotype. Similarly, a broad heterotypic neutralizing antibody response that included all four serotypes was linked to complete absence of K562 cell infection. In contrast, at higher serum dilutions a correlation between breadth of antibody response and heightened immune enhancement emerged, a pattern identical to that observed among control subjects. These findings support the use of live dengue vaccines and protocols that induce broad serotype-specific neutralizing antibody responses, but they also suggest that clinically relevant immune enhancement may not be likely if this is not uniformly achieved after the first immunization.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15315835     DOI: 10.1016/j.vaccine.2004.03.042

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  25 in total

Review 1.  Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas.

Authors:  G William Letson; Pratap Singhasivanon; Eduardo Fernandez; Nihal Abeysinghe; Juan Jose Amador; Harold S Margolis; Robert Edelman
Journal:  Hum Vaccin       Date:  2010-10-01

2.  Forecasting dengue vaccine demand in disease endemic and non-endemic countries.

Authors:  Ananda Amarasinghe; Ole Wichmann; Harold S Margolis; Richard T Mahoney
Journal:  Hum Vaccin       Date:  2010-09-01

3.  Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization.

Authors:  Annette A Kraus; William Messer; Laura B Haymore; Aravinda M de Silva
Journal:  J Clin Microbiol       Date:  2007-09-05       Impact factor: 5.948

4.  An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.

Authors:  Akane Urakami; Mya Myat Ngwe Tun; Meng Ling Moi; Atsuko Sakurai; Momoko Ishikawa; Sachiko Kuno; Ryuji Ueno; Kouichi Morita; Wataru Akahata
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

5.  Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity.

Authors:  Susana V Bardina; Paul Bunduc; Shashank Tripathi; James Duehr; Justin J Frere; Julia A Brown; Raffael Nachbagauer; Gregory A Foster; David Krysztof; Domenico Tortorella; Susan L Stramer; Adolfo García-Sastre; Florian Krammer; Jean K Lim
Journal:  Science       Date:  2017-03-30       Impact factor: 47.728

Review 6.  Advances and challenges towards a vaccine against Chagas disease.

Authors:  Israel Quijano-Hernandez; Eric Dumonteil
Journal:  Hum Vaccin       Date:  2011-11-01

7.  Human FcγRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection.

Authors:  Kobporn Boonnak; Bonnie M Slike; Gina C Donofrio; Mary A Marovich
Journal:  J Immunol       Date:  2013-04-24       Impact factor: 5.422

8.  Role of dendritic cells in antibody-dependent enhancement of dengue virus infection.

Authors:  Kobporn Boonnak; Bonnie M Slike; Timothy H Burgess; Randall M Mason; Shuenn-Jue Wu; Peifang Sun; Kevin Porter; Irani Fianza Rudiman; Djoko Yuwono; Pilaipan Puthavathana; Mary A Marovich
Journal:  J Virol       Date:  2008-02-13       Impact factor: 5.103

9.  Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention.

Authors:  Ana P Goncalvez; Ronald E Engle; Marisa St Claire; Robert H Purcell; Ching-Juh Lai
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-15       Impact factor: 11.205

10.  A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model.

Authors:  Daniel H Libraty; Luz P Acosta; Veronica Tallo; Edelwisa Segubre-Mercado; Analisa Bautista; James A Potts; Richard G Jarman; In-Kyu Yoon; Robert V Gibbons; Job D Brion; Rosario Z Capeding
Journal:  PLoS Med       Date:  2009-10-27       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.